Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06960928 · ClinicalTrials.gov registry record · Phase 3
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
A Phase 3 study of Long COVID-19, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06960928: Recruiting Phase 3 study of Long COVID-19, sponsored by Icahn School of Medicine at Mount Sinai.
NCT06960928 is a Phase 3 study of Long COVID-19 that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 80 participants, below the 7,431-participant average among 14 other Long COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06960928, a Phase 3 study of Long COVID-19, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo. This study aims to evaluate the efficacy of Sirolimus in adults with Long COVID. Efficacy will be evaluated by measuring patient-reported outcomes in response to Sirolimus.
Primary Outcome
The EQ VAS records the patient's self-rated health on a visual analogue scale where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0), with higher scores indicating better health state. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low-dose sirolimus
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-04-18 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 3 |
What NCT06960928 shows while recruiting
NCT06960928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 7,431-participant average among 14 other Long COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Long COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06960928 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06960928 about?
NCT06960928 is a clinical study titled "Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19". The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 a...
What is the current status of trial NCT06960928?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2025-04-18. Estimated completion is 2026-11-30.
What conditions does trial NCT06960928 study?
This clinical trial studies the following conditions: Long COVID-19.
What interventions are being tested in trial NCT06960928?
The interventions under investigation include: Placebo (DRUG), Low-dose sirolimus (DRUG).
Who is sponsoring clinical trial NCT06960928?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06960928 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06960928's enrollment target sits among peer trials
80 11th of 14 higher than 4 of 14 other Long COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
The Long COVID-19 Wearable Device Study
RECRUITING · NA
-
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI